Decline in circulating insulin-like growth factors and mortality in older adults

Cardiovascular health study all-stars study

Robert C. Kaplan, Petra Bùžková, Anne R. Cappola, Howard Strickler, Aileen P. McGinn, Laina D. Mercer, Alice M. Arnold, Michael N. Pollak, Anne B. Newman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The association between changes in IGF-I and IGF binding protein (IGFBP) levels and mortality in older adults is unknown. Study Design: Participants were 997 persons 77 to 100 yr old enrolled in the Cardiovascular Health Study All Stars Study. Plasma levels of IGF-I, IGFBP-1, and IGFBP-3 were assessed at two study examinations (1996-1997 and 2005-2006). Mortality was assessed between 2006 and 2010. Results: Cumulative mortality (CM) was similar among individuals who had at least 10% decreases over time in IGF-I levels (CM = 29.6%), individuals who had at least 10% increases over time in IGF-I levels (CM = 24.7%), and individuals who had IGF-I levels remaining within ± 10% over time (CM = 23.5%). Adjusted for age, sex, race, diabetes, body mass index, creatinine, albumin, and C-reactive protein, decreasing IGF-I level had no significant association with overall cancer mortality or non-cancer mortality. Levels of IGFBP-1 increased markedly over time by38%(median). Individuals with the largest increases in IGFBP-1 level over time had significantly increased risk of mortality. The adjusted hazard ratio per SD of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). Changes in IGFBP-3 levels were not significantly associated with mortality. Conclusion: Among older adults, decreasing IGF-I level over time does not predict subsequent all-cause mortality, whereas increasing IGFBP-1 predicts increased risk of mortality.

Original languageEnglish (US)
Pages (from-to)1970-1976
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume97
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor Binding Protein 1
Stars
Health
Mortality
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Medical problems
C-Reactive Protein
Albumins
Creatinine
Hazards
Confidence Intervals
Plasmas
Neoplasms
Body Mass Index

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Decline in circulating insulin-like growth factors and mortality in older adults : Cardiovascular health study all-stars study. / Kaplan, Robert C.; Bùžková, Petra; Cappola, Anne R.; Strickler, Howard; McGinn, Aileen P.; Mercer, Laina D.; Arnold, Alice M.; Pollak, Michael N.; Newman, Anne B.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 6, 06.2012, p. 1970-1976.

Research output: Contribution to journalArticle

Kaplan, Robert C. ; Bùžková, Petra ; Cappola, Anne R. ; Strickler, Howard ; McGinn, Aileen P. ; Mercer, Laina D. ; Arnold, Alice M. ; Pollak, Michael N. ; Newman, Anne B. / Decline in circulating insulin-like growth factors and mortality in older adults : Cardiovascular health study all-stars study. In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 6. pp. 1970-1976.
@article{8909bd11f4054a4fb51a54e337e695fd,
title = "Decline in circulating insulin-like growth factors and mortality in older adults: Cardiovascular health study all-stars study",
abstract = "Background: The association between changes in IGF-I and IGF binding protein (IGFBP) levels and mortality in older adults is unknown. Study Design: Participants were 997 persons 77 to 100 yr old enrolled in the Cardiovascular Health Study All Stars Study. Plasma levels of IGF-I, IGFBP-1, and IGFBP-3 were assessed at two study examinations (1996-1997 and 2005-2006). Mortality was assessed between 2006 and 2010. Results: Cumulative mortality (CM) was similar among individuals who had at least 10{\%} decreases over time in IGF-I levels (CM = 29.6{\%}), individuals who had at least 10{\%} increases over time in IGF-I levels (CM = 24.7{\%}), and individuals who had IGF-I levels remaining within ± 10{\%} over time (CM = 23.5{\%}). Adjusted for age, sex, race, diabetes, body mass index, creatinine, albumin, and C-reactive protein, decreasing IGF-I level had no significant association with overall cancer mortality or non-cancer mortality. Levels of IGFBP-1 increased markedly over time by38{\%}(median). Individuals with the largest increases in IGFBP-1 level over time had significantly increased risk of mortality. The adjusted hazard ratio per SD of IGFBP-1 change was 1.40 for overall cancer mortality (95{\%} confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95{\%} confidence interval = 1.02, 1.27; P = 0.02). Changes in IGFBP-3 levels were not significantly associated with mortality. Conclusion: Among older adults, decreasing IGF-I level over time does not predict subsequent all-cause mortality, whereas increasing IGFBP-1 predicts increased risk of mortality.",
author = "Kaplan, {Robert C.} and Petra B{\`u}žkov{\'a} and Cappola, {Anne R.} and Howard Strickler and McGinn, {Aileen P.} and Mercer, {Laina D.} and Arnold, {Alice M.} and Pollak, {Michael N.} and Newman, {Anne B.}",
year = "2012",
month = "6",
doi = "10.1210/jc.2011-2967",
language = "English (US)",
volume = "97",
pages = "1970--1976",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Decline in circulating insulin-like growth factors and mortality in older adults

T2 - Cardiovascular health study all-stars study

AU - Kaplan, Robert C.

AU - Bùžková, Petra

AU - Cappola, Anne R.

AU - Strickler, Howard

AU - McGinn, Aileen P.

AU - Mercer, Laina D.

AU - Arnold, Alice M.

AU - Pollak, Michael N.

AU - Newman, Anne B.

PY - 2012/6

Y1 - 2012/6

N2 - Background: The association between changes in IGF-I and IGF binding protein (IGFBP) levels and mortality in older adults is unknown. Study Design: Participants were 997 persons 77 to 100 yr old enrolled in the Cardiovascular Health Study All Stars Study. Plasma levels of IGF-I, IGFBP-1, and IGFBP-3 were assessed at two study examinations (1996-1997 and 2005-2006). Mortality was assessed between 2006 and 2010. Results: Cumulative mortality (CM) was similar among individuals who had at least 10% decreases over time in IGF-I levels (CM = 29.6%), individuals who had at least 10% increases over time in IGF-I levels (CM = 24.7%), and individuals who had IGF-I levels remaining within ± 10% over time (CM = 23.5%). Adjusted for age, sex, race, diabetes, body mass index, creatinine, albumin, and C-reactive protein, decreasing IGF-I level had no significant association with overall cancer mortality or non-cancer mortality. Levels of IGFBP-1 increased markedly over time by38%(median). Individuals with the largest increases in IGFBP-1 level over time had significantly increased risk of mortality. The adjusted hazard ratio per SD of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). Changes in IGFBP-3 levels were not significantly associated with mortality. Conclusion: Among older adults, decreasing IGF-I level over time does not predict subsequent all-cause mortality, whereas increasing IGFBP-1 predicts increased risk of mortality.

AB - Background: The association between changes in IGF-I and IGF binding protein (IGFBP) levels and mortality in older adults is unknown. Study Design: Participants were 997 persons 77 to 100 yr old enrolled in the Cardiovascular Health Study All Stars Study. Plasma levels of IGF-I, IGFBP-1, and IGFBP-3 were assessed at two study examinations (1996-1997 and 2005-2006). Mortality was assessed between 2006 and 2010. Results: Cumulative mortality (CM) was similar among individuals who had at least 10% decreases over time in IGF-I levels (CM = 29.6%), individuals who had at least 10% increases over time in IGF-I levels (CM = 24.7%), and individuals who had IGF-I levels remaining within ± 10% over time (CM = 23.5%). Adjusted for age, sex, race, diabetes, body mass index, creatinine, albumin, and C-reactive protein, decreasing IGF-I level had no significant association with overall cancer mortality or non-cancer mortality. Levels of IGFBP-1 increased markedly over time by38%(median). Individuals with the largest increases in IGFBP-1 level over time had significantly increased risk of mortality. The adjusted hazard ratio per SD of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). Changes in IGFBP-3 levels were not significantly associated with mortality. Conclusion: Among older adults, decreasing IGF-I level over time does not predict subsequent all-cause mortality, whereas increasing IGFBP-1 predicts increased risk of mortality.

UR - http://www.scopus.com/inward/record.url?scp=84861982809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861982809&partnerID=8YFLogxK

U2 - 10.1210/jc.2011-2967

DO - 10.1210/jc.2011-2967

M3 - Article

VL - 97

SP - 1970

EP - 1976

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -